Sellas (SLS) Extends Rally, New Filing Hints at Company Takeover

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits.

Sellas Life Sciences extended its winning streak to a 6th straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition.

In a disclosure, Sellas Life Sciences Group Inc. (NASDAQ:SLS) announced that it made changes to its employment and severance agreements with three of its executive members, namely President and CEO Angelos Stergiou, Chief Finance Officer John Burns, and Chief Development Officer Dragan Cicic, under which they would receive lump sum payment benefits in case of a "change of control."

Burns and Cicic are set to receive lump sum payments equal to 15 months of their base salary, target bonus for the year of termination, and immediate vesting of unvested shares, among others, in case they are terminated by new company owners.

Investors believed the amendments were in preparation for a potential takeover, ahead of Sellas Life Sciences Group Inc.'s (NASDAQ:SLS) looming results of its phase 3 clinical study of its therapy candidate for acute myeloid leukemia (AML).

Last month, Sellas Life Sc

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/sellas-sls-extends-rally-filing-030930721.html)